Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical and biotech industry, indicating a positive outlook on their growth potential and market performance [6]. Core Insights - The ASCO conference showcased significant advancements in domestic innovative drugs, highlighting the competitive edge of Chinese pharmaceutical companies in the global market [4][12]. - The report emphasizes the clinical value and market potential of several key drugs presented at ASCO, including promising results from various companies [4][12]. Summary by Relevant Sections Domestic Key Research Overview - BaiLi Tianheng's BL-B01D1 demonstrated a 35.3% confirmed overall response rate (cORR) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [18]. - DiZhe Pharmaceutical's DZD6008 achieved over 80% overall response rate (ORR) in heavily treated chronic lymphocytic leukemia (CLL) patients, indicating its potential as a new treatment option [4][12]. - FuHong HanLin's PD-L1 ADC showed excellent performance in immune-resistant squamous NSCLC patients, while HLX22 is expected to redefine first-line treatment for advanced gastric cancer [4][12]. - KeLun BoTai's sac-TMT data confirmed long-term survival benefits in third-line EGFR-mutant NSCLC and first-line triple-negative breast cancer (TNBC) [4][12]. - KangNing JieRui's HER2 bispecific ADC demonstrated comparable efficacy and better safety than existing treatments [4][12]. - MaiWei Biotech's 9MW2821 combined with toripalimab is anticipated to be a strong contender in first-line urothelial carcinoma treatment [4][12]. - SanSheng Pharmaceutical updated data on SSGJ-707 for first-line treatment of wild-type NSCLC, with a significant partnership with Pfizer [4][12]. - XinDa Biotech's IBI363 showed potential in activating "cold" tumors, aiming to become a cornerstone drug in immunotherapy [4][12]. - YaSheng Pharmaceutical's Lisaftoclax achieved positive results in patients resistant to venetoclax, filling a treatment gap in myeloid malignancies [4][12]. - ZhengDa TianQing's "DeFu combination" was selected for LBA, potentially offering a new first-line treatment for PD-L1 positive NSCLC [4][12]. - ZeJing Pharmaceutical and ZaiDing Pharmaceutical presented excellent data on ZG006 and ZL-1310 for late-line SCLC treatment, showcasing the global competitiveness of domestic drugs [4][12].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 2025年6月12日舉行之股東週年大會投票表決結果 本公司之香港股份過戶登記處香港中央證券登記有限公司，已就點票事宜獲委任 為股東週年大會之監票員。 全體董事，即董事長兼執行董事徐霆博士及執行董事劉陽女士；非執行董事左敏 先生；及獨立非執行董事郭子建博士、蔚成先生及吳冬先生均親身或以電子方式 出席了股東週年大會。 1 於股東週年大會上提呈的各項決議案的投票表決結果如下： | | 普通決議案 | | 票數(%) | | --- | --- | --- | --- | | | | 贊成 | 反對 | | 1. | 考慮及省覽本公司截至2024年12月31日止年度的 | 547,183,780 | 359,000 | | | 經審核綜合財務報表、本公司董事會報告及核數 | 99.934434% | ...

Group 1 - The core viewpoint of the report is that Guangfa Securities is optimistic about the differentiated biopharmaceutical platform of CStone Pharmaceuticals-B (09966) and the development potential of its ADC drugs, which have shown preliminary clinical efficacy [1] - The company was established in 2015 and focuses on the development, production, and commercialization of innovative anti-tumor biologics, with a highly differentiated internal pipeline covering anti-tumor drugs at various research stages [1] - The first product, KN035 (Envafolimab injection), was launched in November 2021, marking the company's entry into the commercialization phase [1] Group 2 - CStone Pharmaceuticals has developed several globally leading biopharmaceutical technology platforms, including glycoengineered conjugation platform, linker payload platform, bispecific antibody platform, and subcutaneous high-concentration formulation platform, which have differentiated therapeutic advantages [1] - The glycoengineered conjugation platform reduces the production cost of ADC drugs while effectively minimizing toxin release in the circulatory system, enhancing drug safety [1] - Products developed based on this platform, JSKN003 and JSKN016, have entered clinical stages, and the company has upgraded the dual payload technology platform with corresponding products expected to enter clinical trials [1] Group 3 - The HER2 bispecific antibody KN026 is undergoing registration clinical studies for second-line gastric cancer, first-line breast cancer, and neoadjuvant therapy, with a promising path to market [2] - The HER2 bispecific ADC JSKN003 is in phase III clinical trials for breast cancer and platinum-resistant ovarian cancer, demonstrating competitive efficacy in early clinical studies [2] - The HER3/TROP2 bispecific ADC JSKN016 has initiated clinical trials for lung cancer and breast cancer, indicating a broad potential market, while new generation ADCs like JSKN021 (dual payload) and JSKN022 are expected to advance to clinical stages quickly [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 內幕消息公告 控股股東完成配售現有股份 本公告由康寧傑瑞生物製藥（「本公司」）根據香港聯合交易所有限公司證券上市規 則（「上市規則」）第13.09(2)(a)條以及香港法例第571章證券及期貨條例第XIVA部 項下的內幕消息條文（定義見上市規則）作出。 控股股東完成配售現有股份 | | | 佔已發行股份 | | --- | --- | --- | | | 所持股份數目 | 概約百分比 | | 賣方 | 299,400,000(1) | 31.0% | | Sky Diamond Co., Ltd. | 85,750,000 | 8.9% | | Pearlmed Ltd. | 85,750,000 | 8.9% | | 本公司其他股東 | 491,289,807 | 50.9% | | 庫存股 ...

Group 1: Stock Movements and Market Reactions - JunDa Co., Ltd. (02865) fell by 12.69% due to weak fundamentals, expected shareholder sell-off, and cash flow concerns [1] - Rongchang Biopharmaceutical (09995) rose by 4.61% after ASCO announced positive data for RC108 combined with vorinostat, enhancing its commercialization prospects [1] - Datang Gold (08299) increased by 7.27% as it partnered with Wuxi to develop AI mining applications, benefiting from gold's safe-haven demand [1] - Kanglong Chemical (03759) gained 4.35% by investing in a biopharmaceutical fund, strengthening its investment ecosystem [1] - Automotive stocks surged following a significant increase in May's new energy vehicle sales, with Li Auto (2015) rising nearly 6% and Great Wall Motors (2333) up over 3% [1] - Gold stocks led the market as COMEX gold prices returned to $3,400, with Goldman Sachs predicting $4,200, driven by geopolitical tensions [1] Group 2: Company-Specific Developments - Changfei Optical Fiber (06869) rose by 8.34% as its Wuhan base began mass production of 6-inch silicon carbide wafers, achieving a 97% yield rate [2] - China Shipbuilding Defense (00317) increased by 7.58% after securing the highest global new orders from January to April, with Q1 net profit up 1,099% [2] - Hengrui Medicine (00013) rose by 5.09% as SACHI III phase data met expectations, opening up market space for MET amplification lung cancer treatment [2] - Lepu Medical Technology (02157) gained 5.76% following positive ASCO data for its ADC drug MRG003, boosting approval expectations for nasopharyngeal carcinoma [2] - Aidi Kang Holdings (09860) increased by 5.2% after acquiring Suzhou Yuande Youqin to enhance blood disease diagnostics [2] - NetDragon (00777) rose by 5.82% due to its collaboration with Thailand on an AI education platform, attracting investor interest [2] Group 3: Notable Market Trends - China Everbright Holdings (00165) surged over 21% following the enactment of Hong Kong's stablecoin regulations, with Circle's IPO expectations boosting related equity valuations [3] - iFlytek Medical (02506) rose by 6.62% as its medical AI model demonstrated superior accuracy, supported by favorable policies [3] - MicroPort NeuroTech (02172) increased by 9.59% as it initiated clinical research on brain-machine interfaces, benefiting from policy incentives [3] - Longpan Technology (02465) rose by 14.9% after its subsidiary signed a $7.1 billion contract with Yiwei Lithium Energy for lithium iron phosphate [4] - Hansoh Pharmaceutical (03692) gained 3.85% after reaching a global licensing agreement with Regeneron, receiving an $80 million upfront payment [4] Group 4: U.S. Market Highlights - Steel and aluminum stocks surged over 10%-28% as Trump proposed increasing steel tariffs to 50%, benefiting domestic companies [5] - Blueprint Medicines (BPMC.US) rose by 26% following Sanofi's $9.1 billion acquisition, enhancing its rare disease pipeline [5] - BioNTech (BNTX.US) increased by 18% due to a collaboration with Bristol-Myers Squibb, securing a $1.5 billion upfront payment [5] - Applied Digital (APLD.US) surged by 48.46% after signing a $7 billion AI data center lease, validating its business model [5] - Tempus AI (TEM.US) rose by 15% as it launched an AI medical innovation plan, attracting investor interest [7]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 自願公告 於2025年ASCO年會呈列的JSKN003的最新研究成果 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司統稱「本集團」）自願作 出，以知會本集團股東（「股東」）及潛在投資者有關本集團之最新業務進展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，JSKN003的最新研究成果已於 2025年5月30日至6月3日舉行的2025年ASCO年會壁報展示期間公佈。此研究進 展概述如下。 有關JSKN003治療多項適應症的有效性及安全性的匯總分析 JSKN003-101為一項於澳大利亞晚期╱轉移性實體瘤患者中開展的首次人體、 開放性標籤和多中心的I期臨床研究，分為劑量遞增階段和劑量擴展階段。 JSKN003-102為一項於中國晚期實體瘤患者中開展的I期（劑量遞增及劑量擴展）及 II期 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） 於2025年6月2日，本公司董事（「董事」）會（「董事會」）獲本公司其中一名控股 股東（定義見上市規則）Rubymab Ltd.（「賣方」）告知，其已與Morgan Stanley & Co. International plc（「獨家配售代理」）訂立股份配售協議（「配售協議」），據此， 獨家配售代理已同意作為賣方之代理，促使買方購買Rubymab Ltd.持有的合共 14,600,000股本公司現有股份（「股份」）（於本公告日期佔本公司已發行股本總數 （包括庫存股份）之約1.51%），價格為每股股份8.05港元，如未能成功，則由獨家 配售代理自行購買（「配售事項」）。 1 禁售承諾 根據配售協議，賣方已向獨家配售代理承諾，在配售協議所載條件及例外情況的 規限下，於配售協議日期起計直至配售事項交割日期後30天當日（包 ...

本公告乃根據《香港聯合交易所有限公司（「聯交所」）證券上市規則》（「上市規 則」）第17.06A、17.06B及17.06C條而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 根據限制性股份獎勵計劃授出獎勵股份 2 授出日期 2025年5月29日 獎勵承授人數目 三名獎勵董事（彼等均為董事，如上文所載列） 授出獎勵股份之購買價 無 於授出日期股份之收市價 每股8.75港元 茲提述康寧傑瑞生物製藥（「本公司」，連同其附屬公司，統稱「本集團」）日期為 2020年4月14日及2021年3月23日的公告、2024年5月21日的通函及2024年6月12 日舉行之股東週年大會投票表決結果公告（「該等公告及通函」），內容有關（其中 包括）採納限制性股份獎勵計劃（「限制性股份獎勵計劃」）、修訂計劃規則及更新 計劃授權限額。除另有界定者外，本公告所用 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康寧傑瑞生物製藥 呈交日期： 2025年5月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 股東週年大會通告 茲通告康寧傑瑞生物製藥（「本公司」）謹訂於2025年6月12日（星期四）上午十時 正假座中國江蘇省蘇州市蘇州工業園區方洲路175號舉行股東週年大會（「股東週年大 會」），藉以處理下列事項： 普通決議案 「動議： (i) 在下文(ii)段的規限下，一般及無條件批准董事於有關期間（定義見下 文）行使本公司一切權力，根據所有適用法律（包括《公司收購、合併 及股份回購守則》及《香港聯合交易所有限公司（「聯交所」）證券上市 規則》（「《上市規則》」））於聯交所或任何其他股份可能於其上市並就 此獲香港證券及期貨事務監察委員會及聯交所認可的證券交易所購回 本公司股份（「股份」）； – 1 – ALPHAMAB ONCOLOGY (iv) 就本決議案而言： 「有關期間」指由本決議案獲通過當日起至下列較早日期止的期間： – 3 ...